The Department of Justice moved in April to reclassify certain marijuana products from Schedule I to Schedule III under the Controlled Substances Act - the most significant shift in federal drug policy on cannabis since the substance was first scheduled in 1970. The order applies specifically to marijuana with accepted medical use, not to all cannabis products, and it does not extend federal legal status to recreational use. For dispensary operators, multi-state operators, and cannabis investors who have been watching this process for years, the distinction matters enormously.
What Actually Changed - and What Didn't
Schedule I classification has long defined cannabis businesses' most painful operating constraints. The most direct one: Internal Revenue Code Section 280E, which bars businesses trafficking Schedule I or Schedule II controlled substances from deducting ordinary business expenses on their federal tax returns. Payroll, rent, marketing, POS systems, compliance software - none of it deductible. Cannabis operators have been absorbing that burden for years while their counterparts in alcohol, tobacco, and pharmaceuticals write off the same expenses without restriction.
Schedule III status, where drugs like anabolic steroids and Tylenol with codeine currently sit, carries no equivalent 280E prohibition. If the rescheduling holds and the IRS follows suit in its guidance, medical cannabis operators in the 40 states and Washington, D.C., that authorize medical programs could see their effective federal tax burden drop substantially. That's not a rounding error - for a mid-size dispensary carrying $3 million in annual operating costs currently disallowed as deductions, the financial impact of deductibility is real money.
Here's the catch, though: the April order is narrow. It targets marijuana with accepted medical use. Recreational cannabis operations - which account for the majority of licensed adult-use retail in the 24 states and D.C. that allow it - don't automatically move with it. Whether the IRS interprets the rescheduling as relieving 280E liability for the recreational side of a dual-license operation remains an open question. Operators running both medical and adult-use retail under one roof should not assume their entire tax position just changed.
The State-Federal Gap Isn't Going Away
What's striking here is how little the structural conflict between state and federal cannabis law actually resolves under this rescheduling. Forty states and D.C. already authorized medical marijuana programs before this order. Only Idaho maintains a complete prohibition on cannabis products. The practical reality for most dispensary operators hasn't been a federal enforcement crisis day-to-day - the federal government has, for more than a decade, directed its enforcement resources elsewhere and has been barred by congressional budget riders from using DOJ funds to interfere with state medical marijuana programs.
In practice, though, the state-federal gap creates compliance friction that affects nearly every layer of cannabis operations. Banking access remains restricted because most financial institutions operate under federal charter, and financial regulators have not signaled that rescheduling changes their risk calculus on cannabis deposits or business accounts. Cashless payment infrastructure - the workaround ecosystem of PIN debit, ACH, and closed-loop solutions that dispensaries rely on at the point of sale - exists precisely because federal banking law hasn't caught up to state-legal cannabis commerce. Rescheduling to Schedule III doesn't directly address any of that.
Interstate commerce stays prohibited. A licensed cultivator in California still cannot legally ship flower to a licensed wholesale buyer in Nevada. Seed-to-sale tracking systems, manifests, and compliance logs are still structured around state-by-state containment. None of that changes with a scheduling order.
Legal Challenges and Operational Uncertainty
The rescheduling order didn't survive its first month without a challenge. Two groups - Smart Approaches to Marijuana and the National Drug and Alcohol Screening Alliance - filed a federal petition in May to block the move, arguing the DOJ bypassed proper administrative rulemaking procedure and exceeded its authority. The DOJ structured the April order to apply narrowly enough to sidestep formal rulemaking requirements, allowing it to take effect immediately. Whether that legal shortcut holds is now a question for the courts.
The DOJ also announced it will begin a broader rescheduling process starting at the end of June, including administrative hearings, aimed at more comprehensively addressing marijuana's classification. That process is long, procedurally intensive, and subject to political change across administrations. Cannabis operators and their legal teams should treat the current rescheduling as one step in a process, not a settled policy outcome.
For compliance officers and general counsels at multi-state operators, the near-term task is clear: don't restructure operations or tax positions based on the April order alone. Wait for IRS guidance on 280E applicability. Track the litigation. Build scenario planning around both outcomes - the order holds, or the order is enjoined or reversed. Either scenario has real consequences for budgeting, licensing strategy, and investor reporting.
Where Operators Should Focus Right Now
Beyond the tax angle, rescheduling to Schedule III brings cannabis into a regulatory zone where FDA oversight becomes more plausible. Schedule III substances can be lawfully prescribed and are subject to FDA regulation as medications. That framing has long-term implications for product labeling, testing standards, and the COA documentation that licensed dispensaries already manage under state requirements. Whether federal product safety standards eventually layer on top of existing state lab testing mandates is a reasonable question - one that would affect every SKU on a wholesale menu and every batch of product moving through a compliant supply chain.
Public support for broader legalization is substantial - about 64% of Americans supported legalization as of an October 2025 Gallup survey. Congressional action to fully reschedule or legalize cannabis remains, as it has been for years, politically stalled. The executive branch path through administrative rulemaking is slower and more legally exposed. To put it plainly: the federal and state cannabis systems are going to remain misaligned for the foreseeable future, and licensed operators will continue managing that misalignment as a cost of doing business. The April rescheduling order is a meaningful development. It is not a resolution.
